A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06773208
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Hrain Biotechnology Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT06760260
- Locations
- 🇨🇳
First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.
- Conditions
- Acute Myeloid Leukemia (AML)Relapse
- Interventions
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 51
- Registration Number
- NCT06754540
A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia(AML)
- Interventions
- Drug: CAR-T cells（ chimeric antigen receptor T cells）
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- He Huang
- Target Recruit Count
- 24
- Registration Number
- NCT06709131
- Locations
- 🇨🇳
The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
Assessing Refractoriness and Infectious Survival Events in AML
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 280
- Registration Number
- NCT06709235
- Locations
- 🇫🇷
Hopital Lyon Sud, Pierre Bénite, France
Ivosidenib as Post-HSCT Maintenance for AML
- Conditions
- IDH1 MutationAcute Myeloid Leukemia (AML)Hematopoietic Stem Cell Transplant (HSCT)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT06707493
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Guangzhou Ruixin Biotechnological Co., LTD
- Target Recruit Count
- 10
- Registration Number
- NCT06702098
- Locations
- 🇨🇳
Guangzhou Ruixin Biotechnology Co., Ltd, Guangzhou city, Guangdong Province, China, China
Creation of a Biocollection of Patients with Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored At the Nantes University Hospital
- Conditions
- Acute Myeloid LeucemiaHigh-risk Myelodysplastic Syndrome (MDS)Acute Lymphoid Leukemia
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT06681363
- Locations
- 🇫🇷
Nantes University Hospital, Nantes, France
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-08-24
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06679582
- Locations
- 🇺🇸
Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Lucile Packard Childrens Hospital-Stanford, Palo Alto, California, United States
🇺🇸Children's Hospital of Colorado, Aurora, Colorado, United States
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Interventions
- Drug: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-06-18
- Target Recruit Count
- 52
- Registration Number
- NCT06660368
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States